Rhabdomyolysis is defined as the dissolution of striped muscle characterized by the leakage of intracellular muscle components into the circulation, which can ultimately lead to renal failure with a possible fatal outcome. Trabectedin is a potential cause of rhabdomyolysis. Herein, we describe a case of rhabdomyolysis in a female patient with recurrent metastatic leiomyosarcoma of the uterus and who had full recovery, and we review the already published cases in order to identify a common pattern of emergence.
RyanD.P., SupkoJ.G., EderJ.P., SeidenM.V., DemetriG., LynchT.J., FischmanA.J., DavisJ., JimenoJ., ClarkJ.W.: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.Clin Cancer Res, 7: 231–242, 2001.
2.
TwelvesC., HoekmanK., BowmanA., VermorkenJ.B., AnthoneyA., SmythJ., van KesterenC., BeijnenJ.H., UitersJ., WandersJ., GomezJ., GuzmánC., JimenoJ., HanauskeA.: Phase I and pharmacokinetic study of Yonelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumors.Eur J Cancer, 39: 1842–1851, 2003.
3.
McMeekinD.S., LisyanskayaA., CrispensM., OzaA.M., BralyP., DoeringD., BayeverE., MichielsB., MarkmanM.: Singleagent tabectedin as second-line therapy of persistent or recurrent endometrial cancer: Results of a multicenter phase II study.Gyn Oncol, 114: 288–292, 2009.
4.
GronchiA., Le CesneA., BuiN.B., PalmeriniE., DemetriG., HohenbergerP., HohlR.J., PilottiS., PerezI., LardelliP.: A phase II clinical trial of neoadjuvant trabectedin in patients with nonmetastatic advanced/round cell liposarcoma (MRCL).J Clin Oncol, 27: 15s, 2009.
5.
Villalona-CaleroM.A., EckhardtS.A., WeissG., HidalgoM., BeijnenJ.H., van KesterenC., RosingH., CampbellE., KraynakM., Lopez-LazaroL., GuzmanC., Von HoffD.D., JimenoJ., RowinskyE.K.: A phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies.Clin Cancer Res, 8: 75–85, 2002.
6.
YovineA., RiofrioM., BlayJ.Y., BrainE., AlexandreJ., KahattC., TaammaA., JimenoJ., MartinC., SalhiY., CvitkovicE., MissetJ.L.: Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.J Clin Oncol, 22: 890–899, 2004.
7.
SkorupaA., BeldnerM., KraftA., MonteroA.J.: Fatal rhabdomyolysis as a complication of ET-743 (yondelis) chemotherapy for sarcoma.Cancer Biol Ther, 6: 1015–1017, 2007.
8.
ForouzeshB., HidalgoM., ChuQ., MitaA., MitaM., SchwartzG., JimenoJ., GómezJ., AlfaroV., LebedinskyC., ZintlP., RowinskyE.K.: Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.Clin Cancer Res, 15: 3591–3599, 2009.
9.
GomezJ., LazaroL.L., GuzmanC., GonzalezA., MissetJ., TwelvesC.: Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743.Proc Am Soc Clin Oncol, 19, 2000.
10.
BreumerJ.H., Lopez-LazaroL., SchellensJ.H., BeijnenJ.H., van TellingenO.: Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).Curr Cl Pharm, 4: 38–42, 2009.
